Sexually Transmitted Disease Market Size is expected to be worth around USD 171 Bn by 2032 from USD 95 Bn in 2022, growing at a CAGR of 6.17% during the forecast period from 2022 to 2032.
In 2025, the STD Market is being revitalized by advancements in vaccine rollouts and pre-exposure prevention. Uptake of HPV vaccination is expanding to include adolescents and mid-age adults, while expedited programs are piloting herpes simplex (HSV) vaccines in at-risk populations. Concurrently, injectable and topical pre-exposure prophylaxis (PrEP) options are being approved for gonorrhea, chlamydia, and syphilis prevention.
Sexual health clinics are combining HPV, HSV vaccines, and multi-STI PrEP in coordinated care plans. These innovations are shifting the STD landscape from reactive treatment to proactive prevention—poised to reduce incidence and reshape sexual healthcare for the next decade.
Click here for more information:
https://market.us/report/sexually-transmitted-disease-market/Key Market Segments
Based on Disease Type
Chlamydia
Gonorrhea
Herpes Simplex Virus
Syphilis
Human Papillomavirus
Cancroid
Other Diseases
Based on Location
Laboratory Testing
Point of Care (POC) Testing
Based on Devices
Laboratory Devices
Point of Care (POC) Devices
Emerging Trends
Expanded adult HPV vaccination programs covered by insurance.
Introduction of candidate HSV vaccines undergoing rollout in high-risk clinics.
Long-acting injectable PrEP targeting bacterial STIs beyond HIV.
Integrated “vaccine + PrEP” offerings at sexual health and community clinics.
Use Cases
A university health center administers HPV vaccines to students aged 27–45.
An LGBTQ+ clinic offers early access to HSV vaccine in an at-risk cohort.
Healthy adults elect for quarterly injectable STI PrEP at a community clinic.
Mobile health units bring combined HPV/PrEP programs to underserved regions.
Locked
